Business context and reporting period
Filing identity: The supplied filing is CryoLife, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed February 21, 2014. This does not match the request metadata naming Artivion, Inc.; the figures below are for CryoLife as identified in the filing.
CryoLife develops cardiac and vascular medical devices and preserves and distributes human tissues for transplantation. Its principal products include BioGlue sealant, PerClot hemostat, revascularization devices, and the HeRO dialysis graft. Preservation services cover cardiac and vascular tissues.
Financial performance and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $140.8 million | $131.7 million |
| Gross margin | $90.4 million; 64% | $85.0 million; 65% |
| Operating income | $13.8 million | $12.6 million |
| Net income | $16.2 million | $7.9 million |
| Diluted EPS | $0.57 | $0.28 |
| Cash from operations | $16.8 million | $19.0 million |
- Revenue grew 7% year over year. Product revenue rose 13% to $76.2 million; preservation-services revenue increased 1% to $64.5 million.
- BioGlue and BioFoam generated $58.0 million, approximately 41% of revenue. HeRO Graft revenue was $5.7 million, up from $3.1 million in 2012; PerClot revenue was $3.5 million.
- Net income included a $12.7 million pretax gain on the sale of Medafor shares and a $3.2 million impairment of the ValveXchange preferred-stock investment. The reported earnings increase therefore materially reflects investment items, not just operating performance.
- Research and development expense rose 16% to $8.5 million; general, administrative, and marketing expense rose 5% to $68.1 million.
- At year-end, cash and cash equivalents were $37.6 million, with $5.35 million in current restricted cash and securities. Working capital was $85.6 million and the current ratio was 5:1.
- The $20 million GE revolving credit facility had no borrowings outstanding; $5 million was restricted under the facility. The agreement was scheduled to expire October 28, 2014. Total liabilities were $29.9 million; shareholders’ equity was $144.7 million.
- Investing activities provided $10.9 million, principally from $15.4 million in Medafor sale proceeds. Financing activities used $3.1 million, including $3.0 million in dividends and $1.5 million in share repurchases.
Material changes versus the prior comparable period
- FY 2013 revenue increased 7%; operating income rose about 10%, while net income more than doubled, largely due to the Medafor gain.
- Gross margin declined approximately one percentage point to 64%, with higher product costs and write-downs partly offsetting revenue growth.
- Cash from operations declined from $19.0 million to $16.8 million, primarily due to working-capital demands, including higher receivables. Cash and cash equivalents nevertheless increased to $37.6 million, aided by Medafor proceeds.
- Medical-device growth was led by BioGlue and HeRO. Cardiac preservation revenue fell 1% for the year, while vascular preservation revenue increased 3%.
- The company fully impaired its $3.2 million ValveXchange preferred-stock investment; its separate $2.0 million secured loan to ValveXchange remained outstanding, with covenant defaults reported.
Outlook, risks, contingencies, and unusual items
- Management expected 2014 revenue growth in PerClot, revascularization technologies, HeRO Graft, and vascular preservation services; cardiac preservation revenue was expected to be comparable to 2013. These are expectations, not quantified company-wide guidance.
- Management expected materially higher R&D spending in 2014, chiefly for PerClot clinical studies, and higher general, administrative, and marketing expense before litigation and business-development costs.
- PerClot had conditional FDA IDE approvals, with management expecting authorization to begin pivotal-trial enrollment in the first half of 2014. U.S. commercialization remained dependent on further regulatory approval; the company estimated $5–6 million of U.S. approval costs over the following years. Medafor/Bard had asserted potential patent infringement, and litigation could be costly.
- Following FDA observations and a 2013 warning letter concerning manufacturing and tissue-processing controls, the FDA began a reinspection in February 2014. Separate Forms 483 followed inspections of Cardiogenesis and Hemosphere. The company said corrective actions were underway but acknowledged potential product availability, cost, and financial effects if regulators were dissatisfied.
- European tissue distribution faced material regulatory uncertainty. CryoLife planned to stop importing tissue into Europe through the U.K. HTA route after March 31, 2014 rather than adopt additional processing requirements; the company was discussing alternative German licensing and import arrangements. The effect on future sales was uncertain.
- Other notable exposures include the defaulted ValveXchange loan and uncertain collateral recovery; up to $8.4 million of possible future Medafor-related payments, subject to escrow claims and milestones; and product, tissue-processing, regulatory, supply, reimbursement, foreign-exchange, and competitive risks.
- The company anticipated continuing quarterly dividends, but payments were subject to cash needs, credit-agreement covenants, and board decisions. The filing reported no legal proceedings under Item 3; it did describe potential future PerClot patent litigation.
Important facts for investors to verify
- Confirm issuer identity: the supplied document is CryoLife’s 2013 10-K, not a filing under the Artivion name in the request metadata.
- Separate recurring operating results from the $12.7 million Medafor gain and $3.2 million ValveXchange impairment when assessing earnings and EPS.
- Check subsequent outcomes of the PerClot IDE, pivotal trial, U.S. approval path, and any Medafor/Bard patent action.
- Track FDA reinspection findings and remediation, and whether European tissue import and distribution arrangements were maintained or replaced.
- Assess cash conversion and working-capital trends, the October 2014 credit-facility expiration and refinancing, and the collectability of the $2.0 million ValveXchange loan.
- Verify realization and timing of any Medafor escrow or earnout proceeds; the stated maximum was not assured.